Fusion Pharmaceuticals Inc. Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount
Fusion Pharmaceuticals Inc. had Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount of $26.70 million as of 2024-03-31, per its 10-Q filed 2024-05-07.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized · last filed 2024-05-07
- 2024-03-31: Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $26.70M.
- 2023-12-31: Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $19.30M.
- 2023-09-30: Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $22.20M.
- 2023-06-30: Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $24.70M.
| Period end | Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount |
|---|---|
| 2024-03-31 | $26.70M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $19.30M 10-K · filed 2024-03-20 |
| 2023-09-30 | $22.20M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $24.70M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $27.40M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $21.60M 10-K · filed 2023-03-16 |
| 2022-09-30 | $25.10M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $27.40M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $31.50M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $24.60M 10-K · filed 2022-03-17 |
| 2021-09-30 | $25.40M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $24.10M 10-Q · filed 2021-08-10 |
| 2021-03-31 | $24.40M 10-Q · filed 2021-05-11 |
| 2020-12-31 | $17.30M 10-K · filed 2021-03-25 |
| 2020-09-30 | $15.80M 10-Q · filed 2020-11-10 |
| 2020-06-30 | $17.40M 10-Q · filed 2020-08-11 |